Amer Alghabban, Msc. Pharmacol., Vice President, GxP Quality Assurance, Compliance and Training, Research & Development, Karyopharm Therapeutics Inc.
Amer has over 26 years’ track record in the pharmaceutical industry. For some time, he was the Assistant Editor for 11 Medical journals. He contributed further to these disciplines by writing “The Pharmaceutical Medicine Dictionary” and “The Dictionary of Pharmacovigilance”. He is currently writing his 3rd book, Dictionary of Clinical & Pharmaceutical Development. Amer is a frequently invited speaker at international congresses: has both presented & chaired at over 82 international congresses, universities, as well as the WHO.
Amer is currently the Vice President GxP Quality Assurance, Compliance and Training at Karyopharm. Concurrently, he is also the Managing Director of GxP Compliance & Training Partners (GCTP) consulting to Pharma companies. His previous positions include: Director, Global Head of Quality Assurance at Merck Serono, Global Head of GxP QA at Arpida, Senior International Clinical Quality Assurance Audit Manager at Novartis and he was the first Pharmacovigilance Compliance Officer of the MHRA.
Amer completed his M.Sc in Pharmacology at Bradford University, Postgraduate studies in Medical Sciences at University College Hospital, Diploma in Biological Sciences from Salford University & Postgraduate Certificate in Clinical Research from Surrey University.
Patrick A. Baeuerle, Ph.D., Managing Director, MPM Capital
Patrick A. Baeuerle joined the VC firm MPM Capital in 2015 as Managing Director Operations. Prior to joining MPM, Patrick served as Vice President, Research, at Amgen, Inc., and General Manager of Amgen Research (Munich) GmbH. From 1998-2012, Patrick served as Chief Scientific Officer for Micromet, Inc., and earlier headed drug discovery at Tularik, Inc., in South San Francisco, USA. From 1993-1996, he was Professor and Chairman of Biochemistry at the Medical Faculty of Freiburg University, Germany, and earlier group leader at the Gene Center in Martinsried, Germany, where he did seminal research on inflammation. Patrick was rated Germany’s most frequently cited biomedical scientist of the decade (1990-1999), and among the top 50 worldwide (1990-1997). A recipient of numerous awards, he holds a Ph.D. in biology from the University of Munich, and performed post-doctoral research with Nobel laureate Dr. David Baltimore at the Whitehead Institute of the Massachusetts Institute of Technology. Since 2000, he is a Honorary Professor of Immunology at Munich University.
Inpyo Choi, Ph.D., Director, Immunology Convergence Center, KRIBB
1975-1979: B.S., Seoul National University
1979-1981: M.S., Seoul National University
1984-1988: Ph.D., University of Alabama
1988-1991: Postdoc., Medical College of Virginia
1991-present: Korea Research Institute of Bioscience and Biotechnology
Daniel Christ, Ph.D., Associate Professor and Director Centre for Targeted Therapy, Immunology Program, Garvan Institute of Medical Research, Sydney
Associate Professor Daniel Christ is Head of Antibody Therapeutics at the Garvan Institute of Medical Research in Sydney. He holds degrees from the Swiss Federal Institute of Technology (ETH) and Cambridge University, where he worked with biotechnology pioneer Sir Gregory Winter on the development of single domain formats. Professor Christ's work focuses on the stability engineering of human antibody reagents for therapeutic purposes.
Dimiter Dimitrov, Ph.D., Senior Investigator, Cancer Inflammation Program, National Cancer Institute, NIH
Dr. Dimitrov joined the National Cancer Institute (NCI) of the National Institutes of Health (NIH), USA, in 1990. There he was tenured as Senior Investigator and appointed at the Senior Biomedical Research Service. His research group includes molecular biologists who are experts in display/screening/libraries methodologies, antibody engineering, and protein biochemistry, and a structural biologist. His major long-term goal is the development of clinically useful therapeutics and vaccines based on human monoclonal antibodies including engineered antibody domains. He has authored and coauthored more than 370 articles cited more than 16,000 times, and is inventor or coinventor of more than 60 inventions, patent applications or patents. See also his web site
Jonathan M. Gershoni, Ph.D., Professor, Cell Research and Immunology, Tel Aviv University
Prof. Jonathan M. Gershoni completed his BSc in Biology and PhD in Biochemistry at the Hebrew University of Jerusalem. He then did Post-doctoral training with Prof. George E. Palade at Yale School of Medicine where he began his research on the interplay of viruses and their targets and the defense mechanisms of the immune system. Returning to Israel in 1983 he joined the Department of Biophysics at the Weizmann Institute of Science where he continued his study of the molecular events that govern viral infection. Based on his understanding of how viruses recognize their targets Prof. Gershoni proposed a new class of anti-viral drugs, “molecular decoys”. As a result of this research he was invited to join the Laboratory of Tumor Cell Biology at the National Institutes of Health in Bethesda, MD to work with Dr. Robert C. Gallo on developing new approaches to AIDS therapy and prevention. In 1990 he returned to Israel as one of the founders of the new Department of Cell Research and Immunology at Tel Aviv University where he has served as chairman (2003-2006). Over the last decade Prof. Gershoni has focused on developing new methods for the rational design of vaccines to such pandemic diseases as AIDS, Hepatitis C, influenza and SARS. Prof. Gershoni continues to investigate the humoral response towards viral pathogens; developing computational methods to profile the IgOme - the complete repertoire of antibodies in polyclonal sera, and developing novel approaches for epitope based vaccines and next generation diagnostics.
Rui Gong, Ph.D., Prof & Head Antibody Engineering Group, Center for Emerging Infectious Diseases, Institutes of Biological Sciences, Wuhan
Dr. Rui Gong now is head of Antibody Engineering Group and professor in Wuhan Institute of Virology, Chinese Academy of Sciences. He got his Ph.D. in microbiology at Wuhan University, and joined National Cancer Institute, National Institute of Health, USA in 2007 for his five-year training as postdoctoral fellow. His lab focuses on development of engineered antibodies including nanoantibodies based on CH2 domain and Fc optimization.
Philip J. Gotwals, Ph.D., Executive Director, Exploratory Immuno-Oncology, Novartis Institutes for BioMedical Research
Dr. Gotwals is currently executive director of exploratory immuno-oncology at Novartis Institutes for BioMedical Research, and has been instrumental in building the company’s immuno-oncology strategic research area, including Novartis’ collaboration with the University of Pennsylvania to develop chimeric antigen receptor (CAR)-T cell therapy. Dr. Gotwals has more than 20 years of experience in the biotechnology and pharmaceutical industries, leading internal and collaborative R&D programs from drug discovery to new drug application filing and participation in the licensing of product candidates. He was formerly vice president of project management at Altus Pharmaceuticals, where he was responsible for all product development project management activities. Prior to his engagement at Altus, he was senior director of program and alliance management at Biogen, where he oversaw leadership of internal and allied early product development teams in the autoimmune, neurology, and oncology therapeutic areas. Dr. Gotwals holds a Ph.D. in genetics from the University of California at Berkeley, and completed postdoctoral research at the Massachusetts Institute of Technology.
Bruce Nianhe Han, Ph.D., Chief Scientific Office, NewBio Therapeutics, China
I received my BS degree in nuclear chemistry in 1982, MS degree in physical chemistry in 1985 both from Peking University, and Ph.D. in organic chemistry from Columbia University in 1990. I conducted postdoctoral research in antibody engineering in Dr. Richard Lerner’s lab (1990-1994), and postdoctoral research in synthetic organic chemistry and medicinal chemistry in Dr. Dale Boger’s Lab (1994-1996), both at The Scripps Research Institute. After working in Amgen for 12 years on small molecule drug discovery and 5 years in ShangPharma as an executive director in medicinal chemistry, I joined NewBio Therapeutics (NBT) in 2013 as Chief Scientific Officer, leading NBT’s ADC drug discovery efforts.
Felix Hart, Scientist, Preclinical Pharmacology & ADCs, Glycotope GmbH
Scientist in Preclinical Pharmacology & ADCs group, joined Glycotope in 2009. Studied Biotechnology at Beuth University of Applied Sciences in Berlin. DAAD and InWEnt fellow for research projects at North Carolina State University, USA and University of Auckland, New Zealand, respectively.
Sean Hu, Ph.D., Founder, Dophen Biomed
Dr Hu is the founder of Dophen Biomed, a biotech arm of China Shijiazhuang Pharmaceutical Group (CSPC), focusing on site-specific protein drug conjugation using engineered enzymes. He also leads the Bio-therapeutics R&D efforts of CSPC. After obtaining his Ph.D. in Biochemistry from Rutgers University in 1994, he had Post-Doctoral training in Metallo Protein Engineering at The Scripps Research Institute before I took a Senior Scientist at Wyeth. Then, he worked his way up from Group leader at Lexicon Pharmaceuticals, Director of Protein Chemistry at Novo Nordisk, Research Manager of Protein Chemistry at Novozymes until he founded Dophen.
Yong-Sung Kim, Ph.D., Professor, Molecular Science and Technology, Ajou University
Dr. Yong-Sung Kim has been a professor of Dept. of Molecular Science and Technology at Ajou University (Suwon, Korea) since 2004. After obtaining Ph.D. degree in Pharmaceutical Sciences in 2002 from the University of Colorado, Denver, he joined the lab of Prof. K. Dane Wittrup at MIT as a post-doc for protein and antibody engineering using yeast surface display. He spent one year (2010-2011) during his Sabbatical at Genentech Inc. (SF, USA), where he worked with scientists at Depts. of molecular oncology and antibody engineering. Dr. Kim’s research focuses on development of next generation antibody platform technology for potent anti-cancer therapeutics, including heterodimeric Fc-based bispecific antibody, solid tumor-penetrating antibody platform, and cytosol-penetrating antibody platform. He also filed numerous domestic and international patents. Three of them have been transferred into industries for commercialization. His website is http://ws.ajou.ac.kr/~bioeng/.
Bong-Kook Ko, Ph.D., Deputy Director, Antibody Therapeutic Research Center, AbClon Inc.
Bong-Kook Ko is a developer of antibody-based therapeutics and now he’s working as deputy director of Antibody Therapeutic Research Center of AbClon Inc. Bong-Kook Ko received his Ph.D. degree from Seoul National University in Biological Science. AbClon Inc. is platform-based Biotech company developing canonical antibody, bispecific antibody and chimeric antigen receptor T cell therapeutics for treatment of cancers and autoimmune diseases in collaboration with domestic and global companies.
Sukmook Lee, Ph.D., Principal Investigator, Research Center, Scripps Korea Antibody Institute
Sukmook Lee is a Principal Investigator of Laboratory of Molecular Cancer Therapeutics in Scripps Korea Antibody Institute (SKAI). He obtained a Ph.D in biochemistry and cellular signaling from Pohang University of Science and Technology (POSTECH), Korea. Prior to joining Scripps Korea Antibody Institute in 2010, he joined National Institute of Health as a post-doc and Seoul National University as research associate professor for participating in more than six years research experience in the field of antibody engineering. Currently, Sukmook and his team have been focused on developing therapeutic antibodies against novel therapeutic targets particularly related to tumor angiogenesis and metastasis in collaboration with a wide range of academic and industrial partners.
Hyung-Kwon (Harry) Lim, Ph.D., Senior Research Scientist, Antibody Engineering, MOGAM Biotechnology Institute
Dr. Hyung-Kwon (Harry) Lim is leading the antibody engineering at Mogam Biotechnology Institute as a Senior Research Scientist. Dr. Lim is a biochemical and biomolecular engineer with over 20 years of experience in the discovery of early stage protein biologics, therapeutic antibodies, and their platform technologies. Currently, he is coordinating several discovery projects and functional teams relating to the development of antibody therapeutics. He received his Ph.D. from Seoul National University focusing on the study of heterologous protein expression system and biomolecular engineering. Prior to leading an antibody engineering at Mogam, Dr. Lim studied the membrane-anchored antibody displaying system at Cornell University as a postdoctoral research associate.
Ji-Young Min, Ph.D., Principal Investigator, Group Head, Respiratory Viruses Research Laboratory, Discovery Biology Department, Institut Pasteur Korea, Republic of Korea
Ji-Young Min, Ph.D. joined the Institut Pasteur Korea in November 2011 as Group Head of Respiratory Viruses Research Laboratory in Discovery Biology Department. In this role, she is responsible for the development of translational disease intervention strategies for emerging and re-emerging strains of human respiratory viruses. To this end, she is taking chemical genomics and RNA interference (RNAi) approaches to understand the host-pathogen relationship in an effort to simultaneously identify new targets and potential therapeutic small molecule compounds.
Prior to joining Institut Pasteur Korea, she worked on vaccine development and investigated the molecular mechanism of influenza pathogenesis. She served as Staff Scientist and Research Fellow at the National Institutes of Health (NIH) in US, where she performed research focused on the generation of live attenuated reassortant influenza vaccine candidates against avian influenza viruses that have pandemic potential and evaluation of these vaccines in preclinical studies and clinical trials.
Dr. Min graduated from University of Texas at Austin with a Doctorate in Microbiology and Molecular Biology in 2005. During her graduate and postdoc research she had focused on the pathogenesis of influenza A viruses with specific emphasis on the functional interactions of the viral NS1A protein with cellular antiviral proteins.
Julia Neugebauer, Ph.D., Asst Director, Discovery, Alliances & Technologies, Morphosys AG
Dr. Julia Neugebauer currently holds the position of Associate Director and Leader Discovery Projects at the MorphoSys AG, where she heads a team responsible for antibody discovery projects including target validation, antibody selections, functional characterization and engineering up to lead selection. Prior to that position Julia Neugebauer worked at MorphoSys as Project Team Leader for Customer Projects. Altogether she has 10 years of experience in the field of antibody discovery and engineering. Julia Neugebauer studied biochemistry at the University of Regensburg and at the New York University and earned a PhD from the Ludwig-Maximilians-Universität in Munich.
Johan Nilvebrant, Ph.D., Researcher, Protein Technology, Royal Institute of Technology (KTH)
Johan Nilvebrant has contributed to the development of the novel ADAPT alternative scaffold derived from streptococcal protein G; he recently finished a postdoc in Dev Sidhu’s lab at the University of Toronto and is currently a researcher at the Royal Institute of Technology in Stockholm.
Sofie Pattijn, CTO, ImmunXperts
Sofie Pattijn (CTO, ImmunXperts) has over 20 years of experience in the field of immunogenicity assessment (vaccines and biotherapeutics) and in vitro assay development. She has extensive hands-on lab experience and has managed and coached several In Vitro teams over the last decade. From 2008 till 2013 she was Head of the In Vitro Immunogenicity group at AlgoNomics (Ghent, Belgium) and Lonza Applied Protein Services (Cambridge, UK). Prior to that, she worked at Innogenetics, Belgium for over 15 years.
Jonas Schaefer, Ph.D., Head, High-Throughput Binder Selection Facility, Department of Biochemistry, University of Zurich
Since 2011, Dr. Schaefer is heading the High-Throughput Binder Selection Facility of the Department of Biochemistry, automating the Ribosome Display technology and various High-Throughput screenings. With his team, he develops new methodologies enabling the generation and screening of several thousand binders per week which are used in numerous international collaborations. Prior to his current position, Jonas performed his PhD studies with Prof. Andreas Plückthun on the engineering of full-lengths IgGs and other antibody fragments in various academic and industrial collaborations, focusing on aspects of stability, aggregation and unfolding kinetics using many biophysical techniques.
William R. Strohl, Ph.D., Vice President and Fellow, Janssen Biotherapeutics, Janssen Research & Development, LLC.
Dr. William R. Strohl received his Ph.D. in Microbiology from Louisiana State University, and worked as a guest researcher at the GBF in Braunschweig, Germany. From 1980 to 1997, he rose from Assistant to Full Professor in the Department of Microbiology and the Program of Biochemistry at The Ohio State University, Columbus, OH. There he pursued the molecular biology and biochemistry of polyketide biosynthesis pathways, particularly doxorubicin, in actinomycetes, and the physiology of E. coli in computer-controlled high cell density fermentations. As part of the latter endeavor, Dr. Strohl designed, implemented, and equipped a P2 fermentation facility at The Ohio State University.
Dr. Strohl moved to Merck in 1997 to lead Natural Products Microbiology, which he did for four years before starting a new department in the field of recombinant monoclonal antibodies. From 2001 to 2008, Dr. Strohl was a leader in Merck’s efforts to develop therapeutic monoclonal antibodies, as well as in-licensing of therapeutic targets and technologies associated with monoclonal antibodies. As part of this effort, Dr. Strohl was the scientific leader in the acquisition and integration of Abmaxis and GlycoFi into the Merck Biologics organization.
In April, 2008, Dr. Strohl became leader of Antibody Drug Discovery at Centocor (J&J). Concomitant with the evolution of Biologics at Johnson & Johnson to serve additional therapeutic areas beyond Immunology and Oncology, in 2009 Dr. Strohl was named as VP and Head, Biologics Research, the biologics discovery department within the Biotechnology Center of Excellence. In 2013, Dr. Strohl was named as VP and Head, Biotechnology COE, now Janssen BioTherapeutics, Janssen R&D. Dr. Strohl has 140 publications and 18 issued patents, has edited two books, and wrote a book entitled “Therapeutic Antibody Engineering: Current and Future Advances Driving the Strongest Growth Area in the Pharma Industry”, which was published in October, 2012.
Chengbin Wu, Ph.D., CEO, Epimab
Prior to joining Epimab, Dr. Chengbin Wu was the Chief Scientific Officer and President of R&D at Shanghai CP Guojian Pharmaceutical Co., a leading China-based biopharmaceutical company focusing on developing therapeutic antibodies to treat various diseases. Before that, he was the Senior VP Biologics at ChemPartner, where he built a world-class antibody R&D platform. Before that he was a Volwiler Associate Fellow at Abbott laboratories where he led several biologics programs into the clinic. Dr. Wu has extensive experience in engineering and therapeutic development of monoclonal antibodies. He is the primary inventor of the DVD-Ig technology, a novel bi-specific antibody-based technology platform for developing next generation protein therapeutics. Dr. Wu received his Ph.D. degree from the University of Georgia, USA, and postdoctoral training at Beth Israel Deaconess Medical Center, Harvard Medical School.
Kye Sook Yi, Ph.D., Senior Manager and Team leader, New Antibody Development, R&D, Celltrion
[Senior Manager] with  years of responsibilities in R&D center in Celltrion, Inc.
[Research associate] with  years of responsibilities at The Scripps Research Institute in United States
[Research Professor] with  years of responsibilities at Transplantation Research Institute in Korea
[PostDoc] with  years of responsibilities at Chonbuk National University and Seoul National University in Korea
Pohang University of Science and Technology, Korea Ph.D. in Molecular and Life Sciences
Pohang University of Science and Technology, Korea M.S. in Molecular and Life Sciences
Chungnam National University, Korea B.S. in Biology
Tianlei Ying, Ph.D., Professor, Antibody Engineering and Drug Discovery Group, Key Laboratory of Medical Molecular Virology of Ministries of Education and Health, School of Basic Medical Sciences, Fudan University, China
Dr. Tianlei Ying graduated from Fudan University with a Ph.D. in 2010. He conducted postdoctoral research with Dr. Dimiter S Dimitrov at the National Cancer Institute, NIH from 2010 to 2014. In 2014, he joined the Key Lab of Medical Molecular Virology of MOH/MOE, School of Basic Medical Sciences, Fudan University, as Chief of the Antibody Engineering and Drug Discovery Group. Dr. Ying's research interests include antibody-based therapies for cancer, HIV and other infectious diseases. Currently, he is involved in the development of novel antibody fragments of small size and long half-lives; this technology could also be used for extending serum half-lives of protein therapeutics. He also developed several exceptionally large human antibody libraries, and identified panels of highly potent fully human mAbs. Some of these mAbs against cancer and infectious diseases have been licensed to top biopharmaceutical companies including Merck, and are expected to move into the clinic shortly.
Jin-San Yoo, Ph.D., CEO, President and Founder of PharmAbcine
Dr. Jin-San Yoo is CEO, President and Founder of PharmAbcine. He has >15 years of biopharm/biotech experience. As head of therapeutic antibody division, he established all necessary infrastructure, talented pool and several pipelines at LG Life Sciences R&D Park. As principal investigator at KRIBB, he leaded his research team to focus on development of novel therapeutic antibodies. He found PharmAbcine and succeeded the series A coleaded by Novartis and OrbiMed in the middle of global economy crisis. He continuously leads company to clinical stage biotech and platform holders. He successfully completed several rounds of funding and is pushing hard to be a global leader in the industry.
Dr. Yoo has authored numerous papers in peer reviewed journals, book chapters and he is also an inventor of several patents and patent applications.
Dr. Yoo worked for 3 years as TSRI Senior Associate at The Scripps Research Institute, CA, USA. Before Scripps, he was HHMI Associate at Howard Hughes Medical Institute (HHMI) at Stanford University School of Medicine, CA, USA for 3 years.
Dr. Yoo studied microbiology and organic chemistry as undergraduate at the Georg-August-University Göttingen, Germany. He was trained as Intern, MS, PhD and MPI-Fellow in the field of molecular cell biology at Max-Planck-Institute for BioPhysical Chemistry, Göttingen, Germany.
Paul Youm, J.D., Legal Counsel, SillaJen, Inc.
I graduated from Duke University with a degree in Biomedical Engineering with concentrations in quantitative physiology. I was admitted to the Korean Bar Association after graduating from Sogang University Law School in Korea, after which I joined a local law firm, practicing general corporations law as well as representing multiple Korean medical centers and hospitals in medical malpractice and administrative lawsuits. After joining SillaJen, I have been serving as the legal counsel within its business development unit, actively involved in the company’s general business development endeavors including licensing deals and alliance management.
Zhenping Zhu, MD, Ph.D., EVP, Global Biologics R&D, Kadmon Corporation, LLC.
Dr. Zhenping Zhu is currently Executive Vice President, Global Biologics R&D, Kadmon Corporation, New York, and President of Kadmon China. Prior to joining Kadmon, Dr. Zhu was Vice President and Global Head, Protein Sciences and Design, at Novartis from February 2009 to July 2010. At Novartis, Dr. Zhu established and led research groups globally in Basel (Switzerland), Cambridge (US), and Shanghai (China), and was responsible for the discovery, design and selection of novel biologic drugs, including monoclonal antibodies, recombinant proteins and engineered molecules that address diseases of high unmet need. From 1996 to 2009, Dr. Zhu was Vice President of Antibody Technology and Immunology at ImClone Systems, and has led research teams that successfully discovered and engineered several novel antibodies that entered clinical development for oncology indications, including cetuximab (Erbitux), ramucirumab (Cyramza) and necitumumab (Portrazza), three FDA-approved antibodies for the treatment of colorectal, gastric, non-small cell lung cancers, and head and neck cancers. Dr. Zhu is the inventor of Cyramza and Portrazza.
Dr. Zhu earned his medical degree from Jiangxi Medical College and his MSc in Pharmacology from the Institute of Hematology, Chinese Academy of Medical Sciences and Peking Union Medical College. He received his PhD in Immunology and Pathology from Dalhousie University, and performed his postdoctoral work in antibody/protein engineering at Genentech Inc. Dr. Zhu has been working in the area of antibody technologies and biotherapeutics for over 30 years, and has published more than 180 peer-reviewed scientific articles, including original research papers, invited reviews and book chapters.